News & Analysis on the Clinical Development and Manufacture of Large Molecule Drugs
Biopharma firms, particularly those producing insulin and five of its analogues, have another option in the market of sub-2 micron solid-core chromatography columns with a recent offering from Waters.
With the Chinese NAP (nucleic acid purification) market expected to grow more than 8% over the next year and no clear market leaders, companies are looking to take control of the industry space.
Europe may soon approve the first biologic made according to quality by design (QbD) principles, but opinions are still split over whether the approach should even be applied to biopharmaceuticals.
Industry has been slow to implement single-use technologies for microbial cultivations, according to Sartorius which has launched a new bioreactor gas sensor.
Regeneron plans to turn a former computer plant in Ireland into a biologics manufacturing hub to boost MAb production capacity.
Stem cell therapeutics firm ReNeuron will conduct clinical development and – eventually – manufacturing at a new UK base in Wales in a move facilitated by Arthurian Life Sciences.